ENDOCRINE PUBLICATIONS & ABSTRACTS
Endocrine data
Evidence / Endocrine
MammaPrint UltraLow from FLEX Study, Graham et al., SABCS 2023 Abstract
SABCS 2023, PO1-02-11 Authors: Cathy Graham et al.
Read MoreLESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- breast cancer at very low risk of metastasis
Publication: ASCO 2023, Abstract TPS615 Authors: Elise Deluche, Stefan Michiels, Daniele Fric, Christophe Perrin, Caroline Bailleux, Thomas Bachelot, Pascal Ko Kivok Yun, Gaetan De Rauglaudre, Marie-Ange Mouret-Reynier, Romauld Le Scodan, Ines Vaz-Luis, Magali Lacroix-Triki, Clara Guyonneau, Fabrice Andre
Read MoreFOCUS Trial: Validation of MammaPrint for ≥ 70yrs w/ UltraLow risk of distant recurrence
J Geriatr Oncol. 2022 Nov;13(8):1172-1177 Authors: Noordhoek et al.
Read MoreIKA Trial: MammaPrint UltraLow & Limited Systemic Endocrine Overtreatment
IKA Trial, Breast Cancer Res Treat, 2022; 194(2): 265-278 Authors: Opdam, et al.
Read MoreMINDACT: Outcomes of any adjuvant systemic treatment in ESBC
Annals of Oncology, Volume 33, Issue 3, March 2022, Pages 310-320 Authors: Lopes Cardozo et al.
Read MoreMINDACT Trial: Outcome of Patients with UltraLow Risk, JCO 2022
Journal of Clinical Oncology, Volume 40, Number 12, January 21, 2022 Authors: Audeh et al.
Read MoreUse of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS: Laura J. Esserman, MD, MBA; Christina Yau, PhD; Carlie K. Thompson, MD; Laura J. van 't Veer, PhD; Alexander D. Borowsky, MD; Katherine A. Hoadley, PhD; Nicholas P. Tobin, PhD; Bo Nordenskjöld, MD, PhD; Tommy Fornander, MD, PhD; Olle Stål, PhD; Christopher C. Benz, Read More
